Investigational drug · Phase 2
ODM-216
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumors Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ODM-216"
First trial start
2026
Sep 3, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ODM-216", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ODM-216" as an intervention, largest first.
Orion Corporation, Orion PharmaIndustry
NCT07805252 · 195 participants (planned) · Start Sep 3, 2026 · Primary completion Jan 10, 2028
Drug: ODM-216 · For: Advanced Solid Tumors Cancer
Sites: Logroño, Spain; Madrid, Spain; Barcelona, Spain · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Tumors Cancer
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
- GT201Phase 22 trials
Grit Biotechnology · Advanced Solid Tumors, Advanced Solid Tumors Cancer
- KHN922Phase 21 trial
Chengdu Kanghong Biotech Co., Ltd. · Advanced Solid Tumors Cancer
- NDI-219216Phase 21 trial
Nimbus Wadjet, Inc. · Advanced Solid Tumors Cancer, MSI-H Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.